國家衛生研究院 NHRI:Item 3990099045/13005
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 856704      在线人数 : 832
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/13005


    题名: TLR9 binding to beclin 1 and mitochondrial SIRT3 by a sodium‐glucose co‐transporter 2 inhibitor protects the heart from doxorubicin toxicity
    作者: Wang, CY;Chen, CC;Lin, MH;Su, HT;Ho, MY;Yeh, JK;Tsai, ML;Hsieh, IC;Wen, MS
    贡献者: Institute of Cellular and Systems Medicine
    摘要: Large cardiovascular outcome trials have reported favorable effects of sodium‐glucose co-transporter 2 (SGLT2) inhibitors on heart failure. To study the potential mechanism of the SGLT2 inhibition in heart failure, we used the murine doxorubicin‐induced cardiomyopathy model and identified the toll‐like receptor 9 (TLR9), NAD‐dependent deacetylase sirtuin‐3 (SIRT3), and Beclin 1, acting in a complex together in response to empagliflozin treatment. The interactions and implications in mitochondrial function were evaluated with TLR9 deficient, SIRT3 deficient, Beclin 1 haplodeficient, and autophagy reporter mice and confirmed in a patient with SIRT3 point mutation and reduced enzymatic activity. The SGLT2 inhibitor, empagliflozin, protects the heart from doxorubicin cardiomyopathy in mice, by acting through a novel Beclin 1‐toll‐like receptor (TLR) 9‐sirtuin‐(SIRT) 3 axis. TLR9 and SIRT3 were both essential for the protective effects of empagliflozin. The dilated cardiomyopathy patient with SIRT3 point mutation and reduced enzymatic activity is associated with reduced TLR9 activation and the absence of mitochondrial responses in the heart after the SGLT2 inhibitor treatment. Our data indicate a dynamic communication between autophagy and Beclin 1‐TLR9‐SIRT3 complexes in the mitochondria in response to empagliflozin that may serve as a potential treatment strategy for heart failure.
    日期: 2020-10-29
    關聯: Biology. 2020 Oct 29;9(11):Article number 369.
    Link to: http://dx.doi.org/10.3390/biology9110369
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2079-7737&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000592911200001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85094558644
    显示于类别:[王朝永] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    SCP85094558644.pdf5790KbAdobe PDF309检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈